Search

Inavolisib

Inavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers.

Triamcinolone

[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. … [L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients

Respiratory syncytial virus vaccine, adjuvanted

[L46347] On May 3, 2023, it was approved by the FDA for immunization against lower respiratory tract disease (LRTD) as the first respiratory syncytial virus (RSV) vaccine approved in the United States

Prademagene zamikeracel

[A273833,A273838] Patient cells are then transduced ex vivo with a replication-incompetent retroviral vector (RVV) containing the full-length COL7A1 gene, resulting in cells that express functional collagen … [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering

Landiolol

beta-blockers, landiolol possesses unique pharmacodynamic and pharmacokinetic properties, in that it has a rapid onset and short duration of action, and has a greater affinity for β-1 adrenergic receptors over

Cinchocaine

(From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)

Azosemide

Azosemide is a loop diuretic used to treat hypertension, edema, and ascites.

Oxilofrine

Oxilofrine is used in combination with DB11609 as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.

Sodium borate

Oxycodegol

Nektar Therapeutics has filed an application for FDA approval of Loxicodegol for use in the treatment of chronic lower back pain [L3263]